Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study.
Int Urol Nephrol. 2014 Aug; 46(8):1495-9.IU

Abstract

PURPOSE

Desmopressin is used widely to treat nocturnal polyuria (NP), but there is concern of hyponatremia especially in elderly patients. This study aimed to evaluate the safety and efficacy of long-term desmopressin treatment in elderly patients with NP.

METHODS

Patients who were ≥65 years old with NP were analyzed. All patients were started on 0.1 mg desmopressin, and the dose was escalated to 0.2 mg depending on patient symptoms. All patients were educated the mechanism of desmopressin. The voiding diary and serum sodium levels were evaluated at baseline, 3-7 days after starting treatment and every 3-6 months. Safety was evaluated by hyponatremia, hyponatremic symptoms and other adverse drug events. The mean changes in number of nocturia and nocturnal urine volume (NUV) were evaluated for efficacy.

RESULTS

A total of 68 patients were included. The mean age was 72.6 (66-85) years. The mean night-time frequency was 3.0 ± 1.8 day, and the mean serum sodium level was 141.2 ± 2.1 mEq/L at baseline. The mean follow-up period was 27.9 months. The mean decrease in serum sodium level was 1.3 ± 3.4 mEq/L at the last follow-up (p = 0.003). Hyponatremia incidence was 4.4 %, and all patients recovered by stopping medication. Severe adverse events were not observed. The mean night-time frequency had decreased by 2.1, and the NUV had decreased by 374.2 ± 261.3 mL at the last follow-up (p < 0.001).

CONCLUSIONS

Desmopressin at doses below 0.2 mg is safe and effective in elderly patients with NP if patients are well informed and are closely followed up.

Authors+Show Affiliations

Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 138-736, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24595604

Citation

Song, Miho, et al. "Safety and Efficacy of Desmopressin for the Treatment of Nocturia in Elderly Patients: a Cohort Study." International Urology and Nephrology, vol. 46, no. 8, 2014, pp. 1495-9.
Song M, Hong BS, Chun JY, et al. Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study. Int Urol Nephrol. 2014;46(8):1495-9.
Song, M., Hong, B. S., Chun, J. Y., Han, J. Y., & Choo, M. S. (2014). Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study. International Urology and Nephrology, 46(8), 1495-9. https://doi.org/10.1007/s11255-014-0679-0
Song M, et al. Safety and Efficacy of Desmopressin for the Treatment of Nocturia in Elderly Patients: a Cohort Study. Int Urol Nephrol. 2014;46(8):1495-9. PubMed PMID: 24595604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of desmopressin for the treatment of nocturia in elderly patients: a cohort study. AU - Song,Miho, AU - Hong,Bum Sik, AU - Chun,Ji-Youn, AU - Han,Ji-Yeon, AU - Choo,Myung-Soo, Y1 - 2014/03/05/ PY - 2013/11/14/received PY - 2014/02/19/accepted PY - 2014/3/6/entrez PY - 2014/3/7/pubmed PY - 2015/5/12/medline SP - 1495 EP - 9 JF - International urology and nephrology JO - Int Urol Nephrol VL - 46 IS - 8 N2 - PURPOSE: Desmopressin is used widely to treat nocturnal polyuria (NP), but there is concern of hyponatremia especially in elderly patients. This study aimed to evaluate the safety and efficacy of long-term desmopressin treatment in elderly patients with NP. METHODS: Patients who were ≥65 years old with NP were analyzed. All patients were started on 0.1 mg desmopressin, and the dose was escalated to 0.2 mg depending on patient symptoms. All patients were educated the mechanism of desmopressin. The voiding diary and serum sodium levels were evaluated at baseline, 3-7 days after starting treatment and every 3-6 months. Safety was evaluated by hyponatremia, hyponatremic symptoms and other adverse drug events. The mean changes in number of nocturia and nocturnal urine volume (NUV) were evaluated for efficacy. RESULTS: A total of 68 patients were included. The mean age was 72.6 (66-85) years. The mean night-time frequency was 3.0 ± 1.8 day, and the mean serum sodium level was 141.2 ± 2.1 mEq/L at baseline. The mean follow-up period was 27.9 months. The mean decrease in serum sodium level was 1.3 ± 3.4 mEq/L at the last follow-up (p = 0.003). Hyponatremia incidence was 4.4 %, and all patients recovered by stopping medication. Severe adverse events were not observed. The mean night-time frequency had decreased by 2.1, and the NUV had decreased by 374.2 ± 261.3 mL at the last follow-up (p < 0.001). CONCLUSIONS: Desmopressin at doses below 0.2 mg is safe and effective in elderly patients with NP if patients are well informed and are closely followed up. SN - 1573-2584 UR - https://www.unboundmedicine.com/medline/citation/24595604/Safety_and_efficacy_of_desmopressin_for_the_treatment_of_nocturia_in_elderly_patients:_a_cohort_study_ L2 - https://doi.org/10.1007/s11255-014-0679-0 DB - PRIME DP - Unbound Medicine ER -